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Leptin plays a crucial role as an indicator of the size
of somatic energy stores (fat mass) and it is a major
contributor to the regulation of energy homoeostasis
(1). Its most important function is to regulate energy
expenditure and food intake. As an adipokine, leptin
also plays multiple functions in reproduction (2,3),
glucose homoeostasis (4,5), bone formation (6,7),
tissue remodelling (8), inﬂammation (9), as well as
in other elements of the endocrine (10,11) and
immune systems (12).
More recently, it has been shown that leptin has
crucial extra-hypothalamic functions on brain struc-
ture and function. In animals, leptin alters structure
in regions such as the midbrain (13,14), the hippo-
campus (15) and the hindbrain (16). Those effects of
leptin on brain structure are determined by its
actions on neurogenesis, axon growth, synaptogenesis
and dendritic morphology, which occur both during
pre- and postnatal life, and are important for the
establishment hypothalamic, hippocampal and corti-
cal pathways (17). In addition, several studies suggest
that leptin has neuroprotective actions, by inhibiting
apoptotic cell death, attenuating cell death, improv-
ing cell survival, protecting against glutamatergic
cytotoxicity, protecting against oxidative stress and
promoting the proliferation of hippocampal progeni-
tor cells (18,19).
Mediated by the synaptic activation of NR2A-con-
taining NMDA (N-methyl-D-aspartate) receptors
and of the mitogen-activated protein kinase MAPK⁄
ERK pathway, leptin regulates the synapse morphol-
ogy of hippocampal neurons, enhancing the motility
and density of dendritic ﬁlopodia (20). Furthermore,
leptin is a potent neurogenic factor not only to hi-
poccampal (21,22), but also to cortical neurons (23).
The effects of leptin on axonal growth are not
restricted to the hippocampus, and are also evident
in the cortex (24). Leptin has additional effects on
the development of oligodendroglial cells (25), which
may contribute to the structural and functional
changes determined by the adipokine. Furthermore,
effects of leptin on brain function may be deter-
mined by its actions not only on structure, but also
on neuron excitability, via the activation as well as
trafﬁcking of ATP-sensitive K
+ channels in the
hypothalamus and Ca
2+-activated K
+ channels in the
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Background: Leptin is a pleiotropic hormone produced mainly by the adipose tis-
sue. Its most well-known effect is to regulate food intake and energy metabolism
within the hypothalamus. More recently, several peripheral and extra-hypothalamic
effects have been described, expanding leptin’s actions far beyond energy balance.
Aims: To review the extra-hypothalamic effects of leptin and their possible clinical
implications. Methods: We did a PubMed search using the terms ‘‘leptin’’ AND
‘‘brain’’ AND ‘‘neuron’’ AND ‘‘glial’’, and selected the most relevant articles.
Results: In extra-hypothalamic sites, leptin has remarkable effects on neurogen-
esis, axon growth, synaptogenesis, denditric morphology, development of oligoden-
droglial cells, neuron excitability, neuroprotection and regulation of beta-amyloid
levels. Those effects have been shown to improve cognition and mood in animal
models of depression and anxiety. In lean humans, leptin levels have been nega-
tively correlated with the development of Alzheimer’s disease. Conclusions: Leptin
has extra-hypothalamic effects that may protect the brain against the development
of mood and neurodegenerative disorders, such as Alzheimer’s disease. Better
understanding of those effects may lead to the development of potential leptin-
based therapies against such conditions.
What’s known
Leptin has hypothalamic and extra-hypothalamic
effects. The latter include actions on neuron
structure and function, as well as on glial cells.
Those effects are neuroprotective and have been
shown to improve cognition in animal models, as
well as in a child with congenital leptin-deﬁciency.
What’s new
This article is a comprehensive compilation of
extra-hypothalamic effects of leptin. We describe
leptin actions on neuronal and glial structure and
function, and discuss how those actions may be
clinically useful for treating neurodegenerative
diseases and mood disorders.
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neuron excitability through yet undeﬁned mecha-
nisms (26,27).
In humans, leptin also has important extra-hypo-
thalamic effects. Six and 18 months of physiological
leptin replacement therapy in adults treated by our
group for congenital leptin deﬁciency led to increases
in grey matter concentration in the anterior cingulate
gyrus, the inferior parietal lobule, and the cerebellum
(28). More importantly, these effects were sustained
over 3 years of leptin replacement and were reversed
after a few weeks of leptin withdrawal (Licinio et al.,
unpublished results). Leptin-induced alterations of
brain structure overlapped anatomically with effects
on the functional magnetic resonance imaging
(fMRI) response to food cues, with reductions of
brain activation in regions linked to hunger (insula,
parietal and temporal cortex) and enhancements of
the activation of regions linked to inhibition and
satiety (prefrontal cortex) ((29) and Licinio et al.,
unpublished results). In leptin-deﬁcient children,
these effects may be even more dramatic. In a 7-
year-old leptin-deﬁcient boy, leptin replacement,
besides leading to improvement of metabolic and
anthropometric parameters, also had a markedly
positive effect on neurocognitive development (30).
Given these irrefutable effects on brain structure
and function, it is reasonable to hypothesise that
leptin may have roles on mood and cognitive
disorders. Systemic and intrahippocampal infusion of
leptin produced an antidepressant-like effect in mice
submitted to chronic stress, through the direct activa-
tion of leptin receptors in the hippocampus (15). It
has also been suggested that leptin has anxiolytic-like
effects in stressed mice (31). Anorexia nervosa is
another disorder that presents with low leptin levels,
which directly leads not only to somatic alterations,
but also to psychopathological, cognitive and sleep
disorders (32). These alterations can, at least partially,
be reversed by leptin treatment. Memory may also be
improved by leptin as local injections of leptin into
the hippocampus facilitate spatial learning, memory
performance and hippocampal long-term potentiation
(LTP, a form of synaptic plasticity) in mice. Leptin
facilitates the conversion of short-term potentiation
into LTP, by enhancing NMDA receptor function,
enhances LTP at hippocampal CA1 synapses, and rap-
idly remodels dendrites, which explain its effects on
hippocampal LTP (26,33–35).
More recently, low leptin levels have been impli-
cated as a direct cause of cognitive impairment,
particularly Alzheimer’s disease (AD). In that case,
the absence of beneﬁcial effects of leptin in the
central nervous system (CNS) would predispose to
cognitive impairment. A small study showed that
patients with AD and vascular dementia have lower
serum leptin levels (36). In a prospective study with
2,871 elderly people, those in the high leptin group
had lesser likelihood of developing cognitive decline
over 4 years than those in the lower group
(OR = 0.66; 95% CI 0.48–0.91, after adjustment for
age, race, gender, education, baseline cognitive
score, hypertension, prior MI, diabetes, number of
days spent in the hospital in the prior 5 years, BMI
and total percentage of body fat) (37). In another
prospective study of 785 healthy persons from the
Framingham cohort and followed for a median of
8.3 years, 111 developed incident dementia and 89
were diagnosed with AD (38). In multivariate mod-
els, higher leptin levels were associated with a lower
risk of dementia and AD (hazard ratio per 1-SD
increase in log leptin was 0.68 [95% CI, 0.54–0.87]
for all-cause dementia and 0.60 [95% CI, 0.46–0.79]
for AD). Participants in the lowest leptin quartile
were at a fourfold higher risk for developing AD in
12 years, compared with the participants in the
highest quartile (25% vs. 6%). In concordance to
previous studies, leptin levels were correlated with
total brain volumes (28,39). However, the protective
effect of leptin against the development of AD was
observed only among lean individuals; and obese
humans, despite having high leptin levels, may not
beneﬁt from protective effects of leptin because of
central leptin resistance. Nevertheless, this is an
important study further evidencing the roles of lep-
tin on brain structure and function.
The adipoinsular axis – with leptin and insulin as
its main components – has important roles on the
regulation of brain function (40). Over the past dec-
ades, several studies have been proposing links among
leptin, obesity, diabetes and AD. The Rotterdam
study and others that followed suggested an increased
risk to develop dementia and AD in patients with
type 2 diabetes mellitus (41,42). In that case, insulin
resistance and low insulin levels in the CNS (interest-
ingly referred as ‘‘diabetes of the brain’’) would lead
to the accumulation of beta-amyloid (the pathologic
hallmark of AD) and cognitive impairment. Cerebro-
vascular and central inﬂammation would contribute
further to the pathogenesis of AD (43).
This state of insufﬁcient insulin signalling and
excess extracellular glucose would i) decrease astro-
cyte glucose uptake; ii) decrease neuronal nitric oxide
synthase and increase the activity of the proinﬂam-
matory inducible nitric oxide synthase, decreasing
energy substrates and oxidant supply of neurons; iii)
impair redox balance by increasing peroxynitrite for-
mation; and iv) worsen the reduced astrocyte supply
and inﬂammation by inhibiting astrocyte AMP-acti-
vated protein kinase, which decreases glycolysis and
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totic ceramides. Diabetes⁄obesity-related hyperleptin-
emia contributes to inhibit astrocyte 5¢ adenosine
monophosphate-activated protein kinase (AMPK)
selectively, worsening the metabolic disruption in
those cells (44).
The importance of leptin and insulin signalling on
cognition and AD was further demonstrated by a
study where Takeda et al. cross-bred APP23 mice (a
well-studied AD mouse model) with ob⁄ob (leptin-
deﬁcient) and NSY mice (a lean model of type 2 dia-
betes). The APP+ -ob⁄ob and the APP+ -NSY mice
had exacerbated cognitive dysfunction, with reduced
brain insulin and impaired Akt phosphorylation – a
key step in insulin signalling (43), and an important
mediator for the proliferation of adult hippocampal
neural progenitor cells (22). Furthermore, APP+
-ob⁄ob mice had more pronounced cognitive impair-
ment, despite having similar insulin levels. Therefore,
in the pathogenesis of AD, both leptin and insulin
may play important roles, which are likely to be
simultaneous and inter-dependent.
Obesity itself is a known risk factor for AD (45).
Obese patients present with several brain tissue deﬁ-
cits, particularly in the frontal and occipital lobes,
anterior cingulate gyrus, hippocampus and thalamus
(46,47). Other changes found in obese patients
include grey matter deﬁcits in the frontal lobes and
postcentral gyri, but enlarged volumes in the orbito-
frontal white matter (48), and neuronal and myelin
abnormalities in the frontal lobes (49). These changes
may be consequence of several underlying factors,
such as hypercortisolemia, reduced exercise, impaired
respiratory function, inﬂammation, cardiovascu-
lar⁄hypertension⁄hyperlipidemia and type 2 diabetes
(46). However, in common obesity, leptin is
increased, which would theoretically be a protective
factor against AD. This is not the case, as a result of
the increased leptin resistance that is observed in
patients with common obesity (50). Therefore, based
on the lack of association between leptin levels and
the development of AD in obese patients observed
by Lieb et al. (38), it is likely that high leptin levels
do not promote satiety nor have neuroprotective
actions in those individuals.
It is now widely known that leptin has several
extra-hypothalamic actions, perhaps more important
than the classic effects on the regulation of food
intake. Protective effects of leptin against AD may be
determined not only by its actions on neuronal
growth and function (Table 1), but also by its ability
to regulate in vitro and in vivo beta-amyloid levels.
Leptin reduces its extra-cellular levels, reduces beta-
secretase activity in neuronal cells (a protease that
cleaves amyloid precursor protein into beta-amyloid),
increases apoE-dependent beta-amyloid uptake and
increases beta-amyloid clearance from the brain to
the blood by binding to megalin⁄LRP2 (a receptor
involved in the endocytic uptake of known carriers of
beta-amyloid) (51). By decreasing the accumulation
of intraneuronal lipids, leptin suppresses amyloido-
genic pathways. In addition, by inhibiting GSK-3b
(a tau kinase), leptin reduces protein tau phosphory-
lation, reducing the formation of neuroﬁbrillary
tangles (another pathological hallmark of AD) (52).
The inhibitory effects of leptin on the formation
of beta-amyloid and neuroﬁbrillary tangles seem to
be mediated by the selective activation of AMPK in
neurons (53). Therefore, leptin has dual effects on
AMPK: it activates the neuronal and inhibits the glial
enzyme. Even among neurons, leptin can inactivate,
instead of activate AMPK in certain cell types, such
as hypothalamic and hippocampal neurons (54). In
fact, AMPK monitors and controls cellular energy
status, and seems to be the link between nutrition,
cognition and survival. Low-grade hippocampal
AMPK activation promotes neurogenesis and
improves cognition, and high-grade hippocampal
AMPK activation promotes neuronal apoptosis and
cognitive impairment (55). Moderate diet restriction
decreases leptin levels, without compromising its sig-
nalling. Severe diet restriction leads to a decrease in
leptin levels and impairment in its signalling, and to









Neuroprotection Inhibition⁄attenuation of apoptotic
cell death
Improvement of cell survival
Protection against glutamatergic
cytotoxicity
Protection against oxidative stress






Reduction of beta-secretase activity
Increase of ApoE-dependent
beta-amyloid uptake
Increase of beta-amyloid clearance
Decrease of amyloidogenic pathways
Reduction of protein tau
phosphorylation
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impairment of eight-arm maze performance. Subse-
quent leptin replacement in those mice reduced
AMPK activation and reversed the impaired maze
performance. The results of this study suggest a role
for leptin as a brake to AMPK overactivity in the
hippocampus to maintain neural function under
energy restriction. In this case, the balance between
leptin and AMPK is essential in determining neuro-
nal proliferation or apoptosis, and cognitive perfor-
mance (55).
The roles of leptin on brain structure and function
are being extensively characterised by studies show-
ing that the human brain is highly neuroplastic and
depends on leptin for its proper development. Addi-
tional studies in different populations need to con-
ﬁrm the role of leptin as a biomarker for
neurodegenerative diseases. After this role is well-
established and fully characterised, leptin replacement
may be regarded as a therapeutic agent in cognitive
diseases, particularly in AD. However, it is ﬁrst nec-
essary to understand better its effects in the human
brain, as well as in other organ systems. For example,
leptin replacement increases T-cell responsiveness
(56), and when in excess, it may lead to the develop-
ment of autoimmune diseases (57). Leptin also stim-
ulates growth and inhibits apoptosis of cancer cells,
and may contribute to the increase in the incidence
of different types of cancers that are observed in
obese individuals, through the activation of JAK2-
linked PI3K⁄Akt and MEK⁄ERK1⁄2 pathways (58).
In addition to better understanding the leptin phys-
iology, central leptin resistance must be overcome to
make leptin therapy effective in obese patients. How-
ever, in case central leptin resistance is overcome, one
should be aware of effects of leptin on metabolic path-
ways. It is possible that exogenous leptin, in addition
to having positive effects on brain structure and func-
tion, may also selectively inhibit the AMPK activity of
astrocytes (the only cell types in the brain capable to
perform beta oxidation of free fatty acids), leading to
impaired energy metabolism and apoptosis (44). Fur-
ther studies need to evaluate effects of leptin on brain
structure, function and metabolism concomitantly to
provide a solid foundation for work aimed at assessing
possible roles of leptin in the experimental treatment
of AD. Based on existing, independent lines of evi-
dence, we believe that the hypothesis that activation
of the leptin pathway may be a viable treatment strat-
egy for AD must be tested.
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